The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.

Autor: Schlander M; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany; Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany; Alfred Weber Institute (AWI), University of Heidelberg, Mannheim, Germany; Institute for Innovation & Valuation (InnoVal(HC)), Wiesbaden, Germany. Electronic address: m.schlander@dkfz.de., van Harten W; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands; Rijnstate Hospital, Arnhem, Netherlands., Retèl VP; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands., Pham PD; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany; Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany., Vancoppenolle JM; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Health Technology and Services Research, University of Twente, Enschede, Netherlands., Ubels J; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany; Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany., López OS; The Support Team, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Quirland C; Health Technology Assessment Unit, Arturo López Perez Foundation, Santiago, Chile; School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Maza F; Health Technology Assessment Unit, Arturo López Perez Foundation, Santiago, Chile., Aas E; Department of Health Management and Health Economics, University of Oslo, Oslo, Norway; Division of Health Services, Norwegian Institute of Public Health, Oslo, Norway., Crusius B; Federal Cancer Patient Aid, Bonn, Germany., Escobedo A; Oncology Care Management, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Franzen N; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Fuentes-Cid J; Cancer Research Department, Arturo López Perez Foundation, Santiago, Chile., Hernandez D; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hernandez-Villafuerte K; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kirac I; Genetic Counseling Unit, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia., Paty A; Department of Medical Information, Centre Henri Becquerel, Rouen, France., Philip T; Organisation of European Cancer Institutes (OECI), Brussels, Belgium; Institut Curie, Paris, France., Smeland S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital Comprehensive Cancer Centre, Oslo, Norway., Sullivan R; Institute of Cancer Policy, King's College London, London, UK., Vanni E; Business Controlling, Humanitas Clinical and Research Center, Milan, Italy; Biomedical Sciences, Humanitas Clinical and Research Center, Milan, Italy., Varga S; Institute for Gastroenterological Tumours, Zagreb, Croatia., Vermeulin T; Department of Medical Information, Centre Henri Becquerel, Rouen, France., Eckford RD; Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Apr; Vol. 25 (4), pp. e152-e163.

Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.

Autor: Vancoppenolle JM; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands; Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, The Netherlands., Koole SN; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands., O'Mahony JF; Organization of European Cancer Institutes (OECI), Brussels B 1000, Belgium; Centre for Health Policy and Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Franzen N; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands; Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, The Netherlands., Burgers JA; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands., Retèl VP; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands; Organization of European Cancer Institutes (OECI), Brussels B 1000, Belgium; Erasmus School of Health Policy & Management Health Technology Assessment (HTA), Erasmus University Rotterdam, The Netherlands., van Harten WH; Netherlands Cancer Institute-Antoni van Leeuwenhoek Amsterdam, The Netherlands; Health Technology and Services Research Department, Technical Medical Centre, University of Twente, Enschede, The Netherlands; Organization of European Cancer Institutes (OECI), Brussels B 1000, Belgium. Electronic address: w.v.harten@nki.nl.

Publikováno v: Drug discovery today [Drug Discov Today] 2023 Aug; Vol. 28 (8), pp. 103620. Date of Electronic Publication: 2023 May 16.